Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soichi Takeda

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Medicine|August 12, 2023
Computational and Experimental Analyses for Pathogenicity Prediction of <i>ACVRL1</i> Missense Variants in Hereditary Hemorrhagic TelangiectasiaToru Iwasa, Akihiro Urasaki, Yuki Kakihana, et al.
International Journal of Molecular Medicine|June 10, 2022
Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axisKoji Murata, Kosuke Kaji, Norihisa Nishimura, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 6, 2022
Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitisMasahide Enomoto, Kosuke Kaji, Norihisa Nishimura, et al.
Internal Medicine (Tokyo, Japan)|March 13, 2020
Isolated Pancreatic Sarcoidosis Diagnosed by Endoscopic Ultrasound-guided Fine-needle AspirationSoichi Takeda, Hideto Kawaratani, Masayoshi Takami, et al.
Journal of Translational Medicine|June 26, 2026
Role of viral and host factors in determining the outcome of HBV-associated acute liver failurePatrizia Farci, Davide De Battista, Ronald E Engle, et al.
Anticancer Research|September 26, 2025
The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular CarcinomaSoichi Takeda, Tadashi Namisaki, Aritoshi Koizumi, et al.
Anticancer Research|October 26, 2022
Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective StudySoichi Takeda, Tadashi Namisaki, Yuki Tsuji, et al.
Anticancer Research|October 3, 2022
Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With LenvatinibYuki Fujimoto, Tadashi Namisaki, Soichi Takeda, et al.
International Journal of Molecular Sciences|September 9, 2022
Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary CholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.
The FEBS Journal|April 8, 2011
Enzymatic toxins from snake venom: structural characterization and mechanism of catalysisTse Siang Kang, Dessislava Georgieva, Nikolay Genov, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Medicine|August 12, 2023
Computational and Experimental Analyses for Pathogenicity Prediction of <i>ACVRL1</i> Missense Variants in Hereditary Hemorrhagic TelangiectasiaToru Iwasa, Akihiro Urasaki, Yuki Kakihana, et al.
International Journal of Molecular Medicine|June 10, 2022
Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axisKoji Murata, Kosuke Kaji, Norihisa Nishimura, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 6, 2022
Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitisMasahide Enomoto, Kosuke Kaji, Norihisa Nishimura, et al.
Internal Medicine (Tokyo, Japan)|March 13, 2020
Isolated Pancreatic Sarcoidosis Diagnosed by Endoscopic Ultrasound-guided Fine-needle AspirationSoichi Takeda, Hideto Kawaratani, Masayoshi Takami, et al.
Journal of Translational Medicine|June 26, 2026
Role of viral and host factors in determining the outcome of HBV-associated acute liver failurePatrizia Farci, Davide De Battista, Ronald E Engle, et al.
Anticancer Research|September 26, 2025
The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular CarcinomaSoichi Takeda, Tadashi Namisaki, Aritoshi Koizumi, et al.
Anticancer Research|October 26, 2022
Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective StudySoichi Takeda, Tadashi Namisaki, Yuki Tsuji, et al.
Anticancer Research|October 3, 2022
Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With LenvatinibYuki Fujimoto, Tadashi Namisaki, Soichi Takeda, et al.
International Journal of Molecular Sciences|September 9, 2022
Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary CholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.
The FEBS Journal|April 8, 2011
Enzymatic toxins from snake venom: structural characterization and mechanism of catalysisTse Siang Kang, Dessislava Georgieva, Nikolay Genov, et al.
Pageof 6